Seminars in Thoracic and Cardiovascular Surgery
Volume 17, Issue 4 , Pages 334-342 , Winter 2005

New Directions in the Medical Management of Heart Failure

  • John D. Harding, MD
    • ,
  • Mariell Jessup, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Mariell Jessup, MD, Medical Director, Heart Failure/Transplantation, University of Pennsylvania School of Medicine, 6 Penn Tower, 34th and Spruce Sts, Philadelphia, PA 19104.

References 

  1. Jessup M , Brozena S . Medical progress (heart failure) . N Engl J Med . 2003;348:2007–2018
  2. Levy D , Kenchaiah S , Larson M , et al.   Long-term trends in the incidence of and survival with HF . N Engl J Med . 2002;347:1397–1402
  3. Cleland JGF , Daubert JC , Erdmann E , et al.  Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators   The effect of cardiac resynchronization on morbidity and mortality in heart failure . N Engl J Med . 2005;352:1539–1549
  4. Moss AJ , Zareba W , Hall J , et al.  Multicenter Automatic Defibrillator Implantation Trial II Investigators   Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction . N Engl J Med . 2002;346:877–883
  5. Bardy GH , Lee K , Mark DB , et al.  Sudden Cardiac Death in HF Trial (SCD-HeFT) Investigators   Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure . N Engl J Med . 2005;352:225–237
  6. Magalski A , Adamson P , Gadler F , et al.   Continuous ambulatory right heart pressure measurements with an implantable hemodynamic monitor (a multicenter, 12 month follow-up study of patients with chronic HF) . J Cardiac Failure . 2002;8:2
  7. Steinhaus DM , Lemery R , Bresnahan DR , et al.   Initial experience with an implantable hemodynamic monitor . Circulation . 1996;93:745–752
  8. Adamson PB , Magalski A , Braunscheig F , et al.   Ongoing right ventricular hemodynamics in HF. Clinical value of measurements derived from an implantable monitoring system . J Am Coll Cardiol . 2003;41:565–571
  9. Compass-HF Investigators . COMPASS-HF Study (implantable hemodynamic monitor reduces heart failure hospital events for many heart failure patients) . 2005; Presented by Dr. Robert Bourge at the Late-Breaking Clinical Trial session, American College of Cardiology Annual Scientific Session; Orlando, Florida. March 8
  10. MERIT-HF Study Group . Effect of metoprolol CR/XL in chronic heart failure (metoprolol CR/XL randomized intervention trial in congestive cardiac failure) . Lancet . 1999;353:2001–2007
  11. CIBIS Investigators . The cardiac insufficiency bisoprolol study II (CIBIS-II) (a randomized trial) . Lancet . 1999;353:9–13
  12. Packer M , Bristow MR , Cohn JN , et al.   The effect of carvedilol on morbidity and mortality in patients with chronic heart failure (U.S. carvedilol heart failure group) . N Engl J Med . 1996;334:1349–1355
  13. Pfeffer MA , McMurray JJ , Velazquez EJ , et al.   Valsartan, captopril, or both in myocardial infarction complicated by HF, left ventricular dysfunction, or both . N Engl J Med . 2003;349:1893–1906
  14. McMurray JJ , Ostergren J , Swedberg K , et al.   Effects of candesartan in patients with chronic HF and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors (the CHARM-Added trial) . Lancet . 2003;362:767–771
  15. Granger CB , McMurray JJ , Yusuf S , et al.   Effects of candesartan in patients with chronic HF and reduced left ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors (The CHARM-Alternative trial) . Lancet . 2003;362:772–776
  16. Pitt B , Zannad F , Remme WJ , et al.   The effect of spironolactone on morbidity and mortality in patients with severe HF. Randomized Aldactone Evaluation Study . N Engl J Med . 1999;341:709–717
  17. Pitt B , Remme W , Zannad F , et al.   Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction . N Engl J Med . 2003;348:1309–1321
  18. Juurlink DN , Mamdani MM , Lee DS , et al.   Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study . N. Engl J Med . 2004;351:543–551
  19. Cohn JN , Tognoni G . A randomized trial of the angiotensin-receptor blocker valsartan in chronic HF . N Engl J Med . 2001;345:1667–1675
  20. Vantrimpont P , Rouleau JL , Wun CC , et al.  SAVE Investigators   Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study . J Am Coll Cardiol . 1997;29:229–236
  21. Sliwa K , Norton G , Kone N , et al.   Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure . J Am Coll Cardiol . 2004;44:1825–1830
  22. Chung E , Packer M , Lo K , et al.   Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate to severe heart failure (results of the ATTACH trial) . Circulation . 2003;107:3133–3140
  23. Cohn J , Pfeffer M , Rouleau J , et al.   Adverse mortality effect of central sympathetic inhibition with sustained-release monoxidine in patients with heart failure . Eur J Heart Fail . 2003;5:659–667
  24. Mehra M , Uber P , Francis G . HF therapy at a crossroad (are there limits to the neurohormonal model) . J Am Coll Cardiol . 2003;41:1606–1610
  25. Mcnamara D , Holubkhov R , Postava L , et al.   Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive HF . J Am Coll Cardiol . 2004;44:2019–2026
  26. Mcnamara D , Holubkov R , Janosko K , et al.   Pharmacogenetic interactions between β-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive HF . Circulation . 2001;103:1644–1648
  27. Fung J , Yu C , Yip G . Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic HF . Am J Cardiol . 2003;92:406–410
  28. Beta-Blocker Evaluation of Survival Trial Investigators . A trial of the beta-blocker bucindolol in patients with advanced chronic HF . N Engl J Med . 2001;344:1659–1667
  29. Domanski M , Krause-Steinrauf H , Deedwania P . The effect of diabetes on outcomes in patients with advanced HF in the BEST Trial . J Am Coll Cardiol . 2003;42:914–922
  30. Ghali J , Krause-Steinrauf H , Adams K . Gender differences in advanced HF (insights from the BEST study) . J Am Coll Cardiol . 2003;42:2128–2134
  31. Eichorn EJ , Grayburn PA , Mayer SA , et al.   Myocardial contractile reserve by dobutamine stress echocardiography predicts improvement in ejection fraction with β-blockade in patients with HF . Circulation . 2003;108:2336–2341
  32. Small K , Wagoner L , Levin A , et al.   Synergistic polymorphisms of B1 and A2C-adrenergic receptors and the risk of congestive HF . N Engl J Med . 2002;347:1135–1142
  33. Kaye D , Smirk B , Finch S , et al.   Interaction between cardiac sympathetic drive and heart rate in HF . J Am Coll Cardiol . 2004;44:2008–2015
  34. Luzier A , Killian A , Wilton J , et al.   Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers . Clin Pharmaco Ther . 1999;66:594–601
  35. Cohn J , Archibald D , Ziesche S , et al.   Effect of vasodilator therapy on mortality in chronic congestive HF (results of a Veterans Administration Cooperative Study) . N Engl J Med . 1986;314:1547–1552
  36. Cohn JN , Johnson G , Ziesche S , et al.   A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of congestive HF . N Engl J Med . 1991;325:303–310
  37. Carson P , Ziesche S , Johnson G , et al.   Racial differences in response to therapy for HF (analysis of the vasodilator HF trials) . J Cardiac Failure . 1999;5:178–187
  38. Exner DV , Dries DL , Domanski MJ , et al.   Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction . N Engl J Med . 2001;344:1351–1357
  39. Dries DL , Strong MH , Cooper RS , et al.   Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic HF in black and white patients . J Am Coll Cardiol . 2002;40:311–317
  40. Taylor AL , Ziesche S , Yancy C , et al.   Combination of isosorbide dinitrate and hydralazine in blacks with HF . N Engl J Med . 2004;351:2049–2057
  41. Cooper RS , Kaufman JS , Ward R . Race and genomics . N Engl J Med . 2003;348(12):1166–1170
  42. Horwich TB , Fonarow GC , Hamilton MA , et al.   Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with HF . J Am Coll Cardiol . 2002;39:1780–1786
  43. Ezekowitz JA , McAlister FA , Armstrong PW . Anemia is common in HF and is associated with poor outcomes (insights from a cohort of 12,065 patients with new-onset HF) . Circulation . 2003;107:223–225
  44. Felker GM , Gattis WA , Leimberger JD , et al.   Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated HF . Am J Cardiol . 2003;92:625–628
  45. Silverberg D , Wexler D , Blum M , et al.   The use of subcutaneous erythropoitin and intravenous iron for the treatment of the anemia of severe, resistant congestive HF improves cardiac and renal function and functional cardiac class and markedly reduces hospitalizations . J Am Coll Cardiol . 2000;35:1737–1744
  46. Silverberg DS , Wexler D , Sheps D , et al.   The effect of correction of mild anemia in severe, resistant congestive HF using subcutaneous erythropoietin and intravenous iron (a randomized controlled study) . J Am Coll Cardiol . 2001;37:1775–1780
  47. Adams KF , Patterson JH , Pina I , et al.   Stamina-HFP (Study of Anemia in a HF Population) registry (rationale, design, and patient characteristics) . J Cardiac Failure . 2003;9:73
  48. Rutherford R , Xie A , Malone S , et al.   Obstructive sleep apnoea in patients with dilated cardiomyopathy (effects of continuous positive airway pressure) . Lancet . 1991;338:1480–1484
  49. Tkacova R , Rankin F , Fitzgerald F , et al.   Effects of continuous positive airway pressure on obstructive sleep apnea and left ventricular afterload in patients with HF . Circulation . 1998;98:2269–2275
  50. Mansfield DR , Gollogly NC , Kaye DM , et al.   Controlled trial of continuous positive airway pressure in obstructive sleep apnea and HF . Am J Respir Crit Care Med . 2004;169:361–366
  51. Kaneko Y , Floras JS , Usui K , et al.   Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea . N Engl J Med . 2003;348:1233–1241
  52. Cosin J , Diez J  TORIC Investigators . Torsemide in chronic heart failure (results of the TORIC study) . Eur J Heart Fail . 2000;4:667
  53. Lopez B , Querejeta R , Gonzalez A , et al.   Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic HF . J Am Coll Cardiol . 2004;43:2028–2035
  54. Fonarow GC , Adams KF , Abraham WT , et al.  ADHERE Scientific Advisory Committee   Risk stratification for in-hospital mortality in acutely decompensated heart failure (classification and regression tree analysis) . JAMA . 2005;293:572–580
  55. Naitoh M , Risvanis J , Balding L , et al.   Neurohormonal antagonism in HF (beneficial effects of vasopressin V1a and V2 receptor blockade and ACE inhibition) . Cardiovasc Res . 2002;54:51–57
  56. Gheorghiade M , Gattis W , O’Connor CM , et al.  Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive HF (ACTIV in CHF) Investigators   Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure (A randomized control trial) . JAMA . 2004;291:1963–1971
  57. Francis G , Tang W . Vasopressin receptor antagonists. Will the vaptans fulfill their promise? . JAMA . 2004;291:2017–2018
  58. Packer M , Carver JR , Rodeheffer RJ , et al.  PROMISE Study Research Group   Effect of oral milrinone on mortality in severe chronic HF . N Engl J Med . 1991;32:1468–1475
  59. Cohn JN , Goldstein SO , Greenberg BH , et al.  Vesnarinone Trial Investigators   A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure . N Engl J Med . 1998;339:1810–1816
  60. Felker GM , Benza RL , Chandler AB , et al.  OPTIME-CHF Investigators   Heart failure etiology and response to milrinone in decompensated heart failure (results from the OPTIME-CHF study) . J Am Coll Cardiol . 2003;41:997–1003
  61. Nieminen MS , Akkila J , Hasenfuss G , et al.   Hemodynamic and neurohormonal effects of continuous infusion of levosimendan in patients with congestive HF . J Am Coll Cardiol . 2000;36:1903–1912
  62. Slawsky MT , Colucci WS , Gottlieb SS , et al.   Acute hemodynamic and clinical effects of levosimendan in patients with severe HF . Circulation . 2000;102:2222–2227
  63. Tachibana H , Cheng HJ , Ukai T , et al.   Levosimendan improves LV systolic and diastolic performance at rest and during exercise after HF . AJP Heart Circ Physiol . 2005;288:914–922
  64. Yu Cm , Chau E , Sanderson JE , et al.   Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in HF . Circulation . 2002;105:438–445
  65. St John Sutton MG , Plappert T , Abraham WT , et al.  MIRACLE Study Group   Effects of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure . Circulation . 2003;107:1985–1990
  66. Bordachar P , Lafitte S , Reuter S , et al.   Echocardiographic parameters of ventricular dyssynchrony validation in patients with heart failure using sequential biventricular pacing . J Am Coll Cardiol . 2004;44:2157–2165
  67. Bristow M , Saxon L , Boehmer J , et al.  Comparison of Medical Therapy, Pacing, Defibrillation in HF (COMPANION) Investigators   Cardiac resynchronization therapy with or without implantable defibrillator in advanced chronic heart failure . N Engl J Med . 2004;350:2140–2150
  68. Steimle AE , Stevenson LW , Chelimsky-Fallick C , et al.   Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced HF . Circulation . 1997;96:1165–1172
  69. Riegel B , Carlson B , Kopp Z , et al.   Effect of a standardized nurse case management telephone intervention on resource use in patients with chronic HF . Arch Intern Med . 2002;162:705–712
  70. Ansari M , Alexander M , Tutar A , et al.   Cardiology participation improves outcomes in patients with new-onset HF in the outpatient setting . J Am Coll Cardiol . 2003;41:62–68
  71. Fonarow GC , Stevenson LW , Walden JA , et al.   Impact of a comprehensive HF management program on hospital readmission and functional status of patients with advanced HF . J Am Coll Cardiol . 1997;30:725–732
  72. Kimmelstiel C , Levine D , Perry K , et al.   Randomized, controlled evaluation of short and long term benefits of heart failure disease management within a diverse provider network. The SPAN-CHF Trial . Circulation . 2004;110:1450–1455
  73. Moyer-Knox D , Mueller TM , Vuckovic K , et al.   Remote titration of carvedilol for HF patients by advanced practice nurses . J Cardiac Failure . 2004;10:219–224
  74. Roth A , Kajiloti I , Elkayam I , et al.   Telecardiology for patients with chronic HF (the SHL experience in Israel) . Int J Cardiol . 2004;97:49–55

PII: S1043-0679(05)00049-3

doi: 10.1053/j.semtcvs.2005.06.016

Seminars in Thoracic and Cardiovascular Surgery
Volume 17, Issue 4 , Pages 334-342 , Winter 2005

Article Tools

* Image Usage & Resolution